Literature DB >> 27846957

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss.

Elise A Olsen1, Douglas Canfield2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27846957     DOI： 10.1016/j.jaad.2016.08.042

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  9 in total

1.  Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System: A Cluster Analysis.

Authors:  Solam Lee; Beom Jun Kim; Chung-Hyeok Lee; Won-Soo Lee
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

2.  Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.

Authors:  Manuel Sanchez-Diaz; Pablo Diaz-Calvillo; Juan-Angel Rodriguez-Pozo; Jesús Tercedor-Sánchez; Maria-Rosa Cantudo-Cuenca; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  Acta Derm Venereol       Date:  2022-06-15       Impact factor: 3.875

3.  Towards gender equity in artificial intelligence and machine learning applications in dermatology.

Authors:  Michelle S Lee; Lisa N Guo; Vinod E Nambudiri
Journal:  J Am Med Inform Assoc       Date:  2022-01-12       Impact factor: 7.942

4.  Dietary Habits in Japanese Patients with Alopecia Areata.

Authors:  Teppei Hagino; Shizuka Okazaki; Naotaka Serizawa; Kaori Suzuki; Mio Kaga; Yohei Otsuka; Erina Mikami; Toshihiko Hoashi; Hidehisa Saeki; Hiroki Matsuda; Hiroshi Mitsui; Naoko Kanda
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-10-28

Review 5.  Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.

Authors:  Brett A King; Maryanne M Senna; Manabu Ohyama; Antonella Tosti; Rodney D Sinclair; Susan Ball; Justin M Ko; Marc Glashofer; Rodrigo Pirmez; Jerry Shapiro
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-31

6.  Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

Authors:  R Winnette; A Banerjee; V Sikirica; E Peeva; K Wyrwich
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-01-25       Impact factor: 9.228

7.  Can the Cytokine Analysis of the Scales on Alopecic Patch Predict the Response to Diphenylcyclopropenone Treatment in Alopecia Areata Patients?

Authors:  Si Hyub Lee; Jong Hyuk Moon; Dae Hyun Ban; Ji Won Byun; Jeonghyun Shin; Gwang Seong Choi
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

8.  Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response.

Authors:  Manuel Sánchez-Díaz; Trinidad Montero-Vilchez; Ahinoa Bueno-Rodriguez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

9.  Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial.

Authors:  Peter R Feldman; Klaus M Fiebig; Charles Piwko; Boris M Mints; Dennis Brown; Deborah J Cahan; Jaime Guevara-Aguirre
Journal:  EClinicalMedicine       Date:  2021-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.